Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
82.37B
Market cap82.37B
Price-Earnings ratio
18.76
Price-Earnings ratio18.76
Dividend yield
0.45%
Dividend yield0.45%
Average volume
968.17K
Average volume968.17K
High today
$792.77
High today$792.77
Low today
$783.61
Low today$783.61
Open price
$786.81
Open price$786.81
Volume
259.87K
Volume259.87K
52 Week high
$792.77
52 Week high$792.77
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

As of today, Regeneron(REGN) shares are valued at $783.71. The company's market cap stands at 82.37B, with a P/E ratio of 18.76 and a dividend yield of 44.9%.

On 2025-12-26, Regeneron(REGN) stock traded between a low of $783.61 and a high of $792.77. Shares are currently priced at $783.71, which is +0.0% above the low and -1.1% below the high.

The Regeneron(REGN)'s current trading volume is 259.87K, compared to an average daily volume of 968.17K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $792.77 and a 52-week low of $476.49.

In the last year, Regeneron(REGN) shares hit a 52-week high of $792.77 and a 52-week low of $476.49.

REGN News

Nasdaq 1d
REGN Factor-Based Stock Analysis - Benjamin Graham

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...

REGN Factor-Based Stock Analysis - Benjamin Graham
TipRanks 3d
Regeneron, Sanofi get marketing authorization for Dupixent from MHLW in Japan

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for D...

Nasdaq 3d
Sanofi: Dupixent Now Approved In Japan For Children Aged 6 To 11 Years

(RTTNews) - Sanofi (SNY, SAN.PA) said The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent or...

Sanofi: Dupixent Now Approved In Japan For Children Aged 6 To 11 Years

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
30%
Sell
3.3%

More REGN News

TipRanks 7d
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical (TEVA) announced that they have reached a settlement and license agreement wit...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.